Showing 3331-3340 of 5646 results for "".
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476950/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated in the equity round and provi
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated significantly in the equity r
- FDA Approval Granted for Eyeris Novel Contact Lenshttps://modernod.com/news/fda-approval-granted-for-eyeris-novel-contact-lens/2476946/Eyeris, a Nashville, Tennessee start-up, announced that it has closed its second round of funding and secured FDA approval for their daily disposable contact lens, which will become available in
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar
- CorNeat Vision Completes Preclinical Phase For Synthetic Cornea and Scleral Patchhttps://modernod.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/CorNeat Vision announced it has completed the preclinical stage of its cornea implant (CorNeat KPro/Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company’s solutions, which also include a glaucoma drainage device, the CorNeat eShunt, will b
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5